Evidence map›Paper›PMID 41589418›Full record

ArticleEuropean journal of neurology2026

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

Xiao Huan, Ran Chen, Lei Jin, Yuan Wang, Yafang Xu, Lei Yang, Caihua Xi, Jianming Zheng, Lijun Luo, Song Yang and 18 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Xiao HuanHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Ran ChenHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Lei JinHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Yuan WangDepartment of Blood Transfusion, Huashan Hospital, Fudan University, Shanghai, China.
Yafang XuHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0002-0140-7051
Lei YangDepartment of Neurosurgery & Neurocritical Care, Huashan Hospital, Fudan University, Shanghai, China.
Caihua XiDepartment of Neurosurgery & Neurocritical Care, Huashan Hospital, Fudan University, Shanghai, China.
Jianming ZhengDepartment of Infectious Diseases, Huashan Hospital, National Medical Center for Infectious Diseases, Fudan University, Shanghai, China.ORCID 0000-0003-1471-9078
Lijun LuoDepartment of Neurology, Wuhan no. 1 Hospital, Wuhan, China.
Song YangDepartment of Neurology, the First People's Hospital of Changzhou, Third Affiliated Hospital of, Soochow University, Changzhou, China.
Jianquan ShiDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Yanping LiuDepartment of Neurology, Zhongnan Hospital of, Wuhan University, Wuhan, China.
Zhe RuanDepartment of Neurology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.ORCID 0000-0002-8190-4022
Wanlong WuDepartment of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID 0000-0003-2727-7950
Wei LiDepartment of Neurology, Army Medical Center of PLA, Army Medical University, Chongqing, China.
Yaoxian YueDepartment of Neurology, Qilu Hospital (Qingdao), Shandong University, Qingdao, China.
Yarong LiHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Wenji JiaDepartment of Neurology, no. 2 Affiliated Hospital, Kunming Medical University, Kunming, China.
Huahua ZhongHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0002-7852-3982
Chong YanHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Jie SongHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Jianying XiHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Song TanDepartment of Neurology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Qilong JiangDepartment of Myopathy, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Zhangyu ZouDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Chongbo ZhaoHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0001-9481-1418
Sushan LuoHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0002-9033-7568
Chinese Myasthenia Gravis Collaborating Group (CMGCG)

Funding

National Key Research and Development Program of China 2022YFC3501303National Key Research and Development Program of China 2022YFC3501305National Natural Science Foundation of China 82471426Shanghai Municipal Hospital Development Center SHDC2023CRD007
6 · The paper itself

Abstract

backgroundMyasthenic crisis (MC) affects 10%-20% of myasthenia gravis patients and is life-threatening with significant economic burden, yet its long-term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1-year clinical outcomes after MC.

methodsThis study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post-MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all-cause mortality, and complications.

resultsThe cohort comprised 277 patients with 282 MC episodes with a follow-up duration of 29.16 ± 15.93 months. The in-hospital mortality was 5.05% (14/277), while the all-cause mortality was 15.16% (42/277). The leading causes of death were septic shock (35.7%) and multiple organ failure (21.4%). Among 247 patients with complete 1-year follow-up, 79.76% (197/247) achieved favorable outcomes. MG-ADL scores reduced from 21.3 ± 2.1 at baseline to 5.5 ± 1.5 at 6 months, and 2.8 ± 1.1 at 1 year post-MC (p < 0.01). Multivariable analysis identified older age at crisis (OR 1.03, p = 0.003), thymoma comorbidity (OR 1.84, p = 0.041), higher comorbidity burden (Charlson Comorbidity Index ≥ 3, OR 2.68, p = 0.003), and prolonged ICU stay (OR 1.03, p = 0.002) as independent predictors for minimal symptom expression non-responders. The most frequent chronic complications included infections (15.2%; predominantly fungal pathogens), gastrointestinal disorders (8.3%), and osteoporosis/fractures (5.1%).

conclusionsThis is the first prospective cohort study to report clinical outcomes in MG patients at post-MC stage, highlighting the importance of disease monitoring and early intervention to improve patient-centred care.

Indexed as

Myasthenia GravisAdultAgedChinaFemaleFollow-Up StudiesHospital MortalityHumansMaleMiddle AgedProspective Studiesclinical outcomesmortalitymyasthenia gravismyasthenic crisispost‐intervention status

Identifiers

PMID41589418
PMCPMC12836041

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.